← Back to Search

GLP-1 Receptor Agonist

SLIMM + Semaglutide for Kidney Disease

Phase 2
Recruiting
Led By Srinivasan Beddhu, M.D.
Research Sponsored by Srinvasan Beddhu
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Six minute walk distance ≥ 300 m and < 600 m
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Glomerular Filtration Rate (eGFR) 20 to <45 mL/min/1.73m^2
Timeline
Screening 3 weeks
Treatment Varies
Follow Up randomization to 12 months
Awards & highlights

Study Summary

This trial is looking at whether two interventions can help people with kidney disease reduce the amount of time they spend sitting down, which has been linked with obesity, diabetes, and death.

Who is the study for?
The SLIMM 2 study is for adults with chronic kidney disease who are overweight, can walk a certain distance, and have moderate to severe reduction in kidney function. Participants need internet access and the ability to do resistance training but cannot be on oxygen therapy or have had recent major medical procedures.Check my eligibility
What is being tested?
This trial tests whether guided resistance training and semaglutide (a diabetes/weight loss medication) can help people with kidney disease reduce sedentary behavior by improving muscle strength and physical function as part of the SLIMM intervention.See study design
What are the potential side effects?
Semaglutide may cause digestive issues like nausea or diarrhea, risk of low blood sugar, pancreatitis, allergic reactions, thyroid tumors in those at risk. Resistance training could lead to muscle soreness or injury if not done correctly.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can walk between 300 to 600 meters in six minutes.
Select...
My kidney function is moderately to severely reduced.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~randomization to 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and randomization to 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Average Change in Sedentary Duration at Months 8, 10 and 12 from Randomization
Secondary outcome measures
Average Change in Body Fat % at Months 6 and 12 from Randomization
Average Change in Six-Minute Walk at Months 6 and 12 from Randomization
Average Change in Stepping Duration at Months 8, 10 and 12 from Randomization
+1 more
Other outcome measures
Average Change in Circulating Protein Markers of Inflammation at Months 6 and 12 from Randomization
Average Change in Lower Extremity Performance Battery Composite Score (LEP-CS) at Months 6 and 12 from Randomization
Average Change in Patient Reported Fatigue at Months 6 and 12 from Randomization
+3 more

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: SLIMM + Guided RT + SemaglutideExperimental Treatment3 Interventions
SLIMM intervention for 3 months, followed by a 9-month intervention of SLIMM, guided resistance training and oral semaglutide
Group II: SLIMM + Guided RT + PlaceboActive Control3 Interventions
SLIMM intervention for 3 months, followed by a 9-month intervention of SLIMM, guided resistance training and oral placebo
Group III: SLIMM + Standard RT + PlaceboPlacebo Group3 Interventions
SLIMM intervention for 3 months, followed by a 9-month intervention of SLIMM, standard-of-care resistance training and oral placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Semaglutide
FDA approved

Find a Location

Who is running the clinical trial?

Srinvasan BeddhuLead Sponsor
2 Previous Clinical Trials
138 Total Patients Enrolled
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,358 Previous Clinical Trials
4,314,918 Total Patients Enrolled
446 Trials studying Obesity
588,782 Patients Enrolled for Obesity
Stanford UniversityOTHER
2,393 Previous Clinical Trials
17,341,080 Total Patients Enrolled
69 Trials studying Obesity
270,028 Patients Enrolled for Obesity

Media Library

Semaglutide (GLP-1 Receptor Agonist) Clinical Trial Eligibility Overview. Trial Name: NCT05173714 — Phase 2
Obesity Research Study Groups: SLIMM + Standard RT + Placebo, SLIMM + Guided RT + Placebo, SLIMM + Guided RT + Semaglutide
Obesity Clinical Trial 2023: Semaglutide Highlights & Side Effects. Trial Name: NCT05173714 — Phase 2
Semaglutide (GLP-1 Receptor Agonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05173714 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is SLIMM a new medication or have there been other tests done with it before?

"The SLIMM clinical trial was conducted in 2018 at the Novo Nordisk Investigational Site. As of now, a total of 18399 clinical trials have been completed. Out of these, 58 are actively recruiting participants. The majority of these studies take place in Salt Lake City, Utah."

Answered by AI

What health condition does SLIMM commonly help alleviate?

"SLIMM is frequently used to help patients manage chronic weight issues. In addition, it can be deployed as part of a treatment plan that includes a reduced-calorie diet, physical activity, and treating at least one other condition related to being overweight."

Answered by AI

Does the FDA sanction SLIMM as a medication?

"While there is some data backing the safety of SLIMM, it only received a 2 because there are no Phase 3 trials supporting its efficacy."

Answered by AI

Are new patients being taken in for this experiment?

"That is accurate. The information available on clinicaltrials.gov suggests that this trial has not yet reached its goal number of participants, as it was last updated less than a month ago. This study is looking for 180 individuals at 2 separate locations."

Answered by AI

How large is the test group for this experiment?

"Yes, the trial is active and recruiting patients at 2 locations. The original posting was on December 1st 2021 with the most recent edit happening on December 20th 2021. They are looking for a total of 180 individuals to participate."

Answered by AI

Are there any other similar trials to this one that have been conducted in the past?

"Since 2018, SLIMM has been the focus of several clinical trials. The first one was sponsored by Novo Nordisk A/S and took place in 2018. It involved 1387 patients. After this initial trial, SLIMM received its Phase 4 drug approval. Today, there are 58 live trials for SLIMM happening in 769 cities across 55 countries."

Answered by AI

Who else is applying?

What site did they apply to?
University of Utah
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
1
Recent research and studies
clinicaltrials.govStudy
Sit Less, Interact and Move More (SLIMM) 2 Study
Srinvasan Beddhu 2021. "Sit Less, Interact and Move More (SLIMM) 2 Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05173714.
~83 spots leftby Dec 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top